This episode delves into Subpart K of 21 CFR Part 211, which provides specific guidance for the handling of returned and salvaged drug products. We explain the regulatory expectations for the inspection, segregation, and documentation of returned items. Furthermore, we explain how the regulation ensure that any product re-entering the supply chain does not compromise safety or efficacy. We present a risk based approach.

The episode emphasizes the importance of a risk-based approach and detailed recordkeeping to justify decisions on product disposition in compliance with GMP standards. We explore real-world examples of how companies handle returned products and the challenges they face in determining whether a product can be safely returned to the market. The discussion highlights the critical role of Subpart K in protecting the integrity of the drug supply chain and safeguarding patient health. The goal is to make sure no bad products are reintroduced.